by Paul McIntosh | Jan 28, 2025 | 2025, Press Releases
The Institute of Podiatrists are delighted to announce their endorsement of Tinexyl PRO. Our Medicines and Procedures Panel (MaPP) were invited to assist with the product review of Tinexyl PRO over a year ago. During this time MaPP have played an active role in...
by Paul McIntosh | Oct 8, 2024 | 2024, Press Releases
NovaBiotics Consumer Health Limited (“NCH”), a division of NovaBiotics Limited (“NovaBiotics” or “the Company”), today announced that it has entered into a distribution agreement with Brand Creations Limited (“BCL, for the rights to commercialise and distribute...
by Paul McIntosh | Sep 6, 2023 | 2023, Press Releases
ABERDEEN 6 SEPTEMBER 2023. NovaBiotics, the clinical-stage biotechnology company announces the appointment of Dr Trevor Phillips to its board as Non-Executive Director. Trevor is a biotechnology leader who previously held board and C-level roles in pharma and Biotech...
by Paul McIntosh | Apr 21, 2022 | 2022, Press Releases
New preclinical data further support the application of NM002 as novel anti-inflammatory-antimicrobial intervention in community acquired pneumonia and also data demonstrate the in vitro safety profile, fungal cell specificity and potential of NP339 in respiratory...
by Paul McIntosh | Dec 8, 2021 | 2021, Press Releases
NovaBiotics’ NM002 (cysteamine bitartrate) Under Investigation in a Phase 3 Study for Community Acquired Pneumonia, Including COVID-19, Influenzas and Bacterial Pneumonias Aberdeen, December 8, 2021. NovaBiotics Ltd, a privately held clinical stage company developing...
by novabioticsadm1n | Nov 1, 2021 | 2021, Press Releases
by Paul McIntosh | Oct 29, 2021 | 2021, Press Releases | 0 comments Highlights new insights into cysteamine’s mechanism of action against Pseudomonas aeruginosa and Burkholderia cenocepacia, further supporting cysteamine’s potential as an antimicrobial intervention in...
Recent Comments